The stock prices of copper miners experienced a downward turn, reflecting the pattern of the red metal’s price itself.

The three-month benchmark copper on the London Metal Exchange declined by 0.2 percent, sitting at $8,130 per tonne.

The dip in copper prices has been attributed to a mixture of challenging factors, including worries over demand from China, a predominant metals consumer.

An accumulation of high inventories, coupled with the continuous strain of a robust dollar and the anticipation of enduringly high interest rates adds to the pressure.

United States listed shares of internationally recognized mining magnates, Rio Tinto (ASX:RIO) and BHP Group, dipped 0.5% and 1%, respectively.

Other copper miners, such as Southern Copper and Freeport-McMoRan, fell 0.9% and 0.6%, respectively.

Canadian miners, First Quantum Minerals and Ero Copper, also reported decreases of 2% and 2.2%, respectively.

Rio Tinto (ASX:RIO) is a global mining giant that specializes in the mining and processing of mineral resources.

Stavely Minerals (ASX:SVY) announced a fiscal year loss after income tax attributable to A$8.9 million contrasting the previous loss of A$14.0 million.

Stavely Minerals is a company that specializes in the exploration of mineral resources.

Shares of Mithra Pharmaceuticals (ASX:MITRA) plummeted over 12% following the release of disappointing H1 results and an outlook reduction for its contraceptive drug, Estelle.

The Belgium-based pharmaceutical firm announced weak sales guidance adjustments for Estelle, reflecting marketing partners' inventory and promotional pricing effects.

The pharmaceutical company’s H1 revenues fell 38% year-on-year to 7 million euros, leading to a broadened net loss of 50.5 million euros.

The anticipated annual revenue for Estelle has been marked down to 8.5 million from the previous 12 million euros.

Despite a rise in dispensed Estelle cycles in the U.S., supply sales to Mayne (ASX:MYX) are yet to fully reflect this due to initial inventory buildup and lower promotional pricing, according to KBC.

Further compounding the bleak financial position, Mithra’s stock has nosedived 46% YTD, inclusive of today’s decline.

Mithra Pharmaceuticals (ASX:MITRA) is a Belgium-based firm specializing in the provision of various pharmaceutical solutions.

Shares of UK-based MGC Pharmaceuticals, traded under the stock symbol MXC, witnessed a 9.5% decrease, with its value dropping to 0.095p.

It was among the top losers across all London stocks.

If this trend continues, the stock is on track for its fifth consecutive day of losses.

MGC Pharma stated that it has encountered significant difficulties in raising funds primarily in the UK, and also in Australia due to market conditions.

The company’s board and management, in response, have committed to designing a restructuring plan to secure long-term financing.

This restructuring plan will aim to decrease the company’s reliance on constant capital raising, thereby enabling the completion of an 18-month work plan.

To date, the stock has experienced an almost 83% decline in its value.

MGC Pharmaceuticals is a biopharmaceutical company that specializes in medicinal cannabis products.

Australian gold stocks (ASX:AXGD) decrease by 1.8%, marking their worst performance since September 5, if the current losses remain steady.

Weaker gold prices are driving the retreat of gold stocks, as the U.S.

dollar and Treasury yields rise, with investors patiently waiting for further data for rate indicators from the U.S.

Federal Reserve.

This resulted in the sub-index reaching its lowest point since September 11.

Major gold miners such as Newcrest Mining (ASX:NCM) and Northern Star Resources (ASX:NST) have seen a decrease in share prices up to 2.1% and 2%, respectively.

Furthermore, Newcrest Mining could be facing its poorest day since July 21 if the current trend continues.

Remarkably, gold stocks have experienced a 12.3% increase this year as of the last closing, in contrast to a 0.5% increase in the benchmark index.

Australian Gold Stocks (ASX:AXGD) refers to shares in companies that are involved in the production of gold.

Shares in Lycaon Resources (ASX:LYN) rose as much as 5.2% to A$0.305, their highest level since September 20, after the company disclosed the intersection of nickel-copper sulphides at its Bow River Project in Western Australia.

Trading was brisk, with over 539,200 shares changing hands, a significant increase compared to the average 30-day volume of 138,611.

After the last close, the company’s stock has risen 5.5% Year to Date.

In short, Lycaon Resources is a mineral exploration company with key operations in Western Australia.

Shares of the Australian gold mining company, Catalyst Metals (ASX:CYL), saw a significant rise of up to 4.17% reaching A$0.500, the highest it has been since September 14.

This represents the company’s largest intraday percentage gain since September 8.

Catalyst Metals (ASX:CYL) and Wolf Contracting have announced that they have resolved a legacy dispute.

The company also pointed out that it would be open to a potential future partnership with Wolf as a contracting partner at the Plutonic Gold Belt, located in Western Australia.

However, as of the time of the last closing, the stock was down 59.3% year to date.

Catalyst Metals (ASX:CYL) is a renowned Australian gold mining company.

Shares of Magnetic Resources surged 12.8% to A$0.835, poised for its best day since August 22 if gains persist.

The firm, dedicated to mineral exploration, announced the discovery of additional thick gold intersections at its Lady Julie North 4 deposit located in Western Australia.

Approximately 58,667 shares have exchanged hands, in contrast to the 30-day average volume of 18,842.

The stock of Magnetic Resources has reached its highest level since September 12.

However, the stock is down nearly 14% year-to-date, as per the closing figures of the last reported session.

Magnetic Resources is a mineral exploration company primarily engaged in the discovery and development of significant mineral resources.

Macquarie analysts predict a downside risk to earnings for dairy company Synlait Milk (ASX:SML), based on a medium-to-long term outlook on A2 milk volume.

Macquarie has cut the price target to A$1.25 from A$1.53, sustaining its ‘underperform’ rating.

This resulted in a 0.8% drop for Synlait at NZ$1.27.

In the previous week, a2 Milk Company announced it would be terminating Synlait’s exclusive production and supply rights for certain infant milk formula products.

The brokerage reduced the FY24 and FY25 EPS estimates by 40% and 24%, respectively.

Of five analysts, two recommend buying the stock, two suggest holding it, and one advises selling; their median price target stands at NZ$2.05 according to LSEG Data.

Synlait has seen a sharp decline of 63.7% year-to-date.

Synlait Milk (ASX:SML) is a New Zealand-based dairy company specializing in milk processing and distribution.

Shares of Australia’s Future First Technologies (ASX:FFT) jumped 29.4% to A$0.011, putting the company on track for its best day since April 27 if the gains continue.

Future First Technologies revealed that its subsidiary, Asset Vision, has had its contract with the Department of Transport and Planning of Victoria (DTP), extended.

This three-year extension is valued at approximately A$1.9 million, continuing a partnership with DTP that has now lasted over 12 years.

As of 0358 GMT, around 1.9 million shares had exchanged hands, a significant increase compared to the average 30-day volume of 193,624 shares.

Despite the day’s increase, the company’s year-to-date losses sit at 57.7%, contrasting against a 0.54% increase in the S&P/ASX 200 index overall.

Future First Technologies (ASX:FFT) is a leading technology firm that specialises in designing and implementing innovative digital solutions.